Real-World Studies
Non-operative rectal cancer management assessed in safety-net cohort
Chavana et alJournal of gastrointestinal oncology
A retrospective study evaluated real-world oncologic outcomes in 49 patients with locally advanced rectal cancer (LARC) managed non-operatively with definitive intent at a single safety-net hospital system over a decade. Most of the cohort would not have met eligibility criteria for contemporary watch-and-wait (W&W) clinical trials due to adverse social determinants of health, comorbidities, or higher-risk oncologic features.
The patient population was racially and ethnically diverse (63% Hispanic, 20% White, 12% Black; 55% male), with 69% lacking health insurance. Reasons for non-operative management included patient preference (49%), suspicion of low-burden metastatic or non-regional nodal disease (35%), and medical comorbidities (16%). Over a median follow-up of 25 months (range, 8–90 months), all patients received radiotherapy and systemic chemotherapy: 76% received long-course chemoradiotherapy (50–55 Gy with concurrent capecitabine) and 24% received short-course radiotherapy (25 Gy in 5 fractions).
At 2 years, local control was 59%, progression-free survival was 43%, and overall survival was 67%. An initial complete or near-complete clinical response was documented in 37% of patients (18/49), among whom 5 experienced local recurrence. Distant-only metastasis constituted the most frequent recurrence pattern. Local failure rates did not differ significantly based on the radiotherapy regimen administered (P=0.51). These findings indicate that organ-preserving, radiotherapy-based strategies can deliver meaningful local control in underserved populations even outside standard trial eligibility criteria and formal surveillance protocols.
Key Takeaways
- In a real-world safety-net cohort of 49 patients with locally advanced rectal cancer managed non-operatively, 2-year local control was 59%, progression-free survival was 43%, and overall survival was 67%.
- An initial complete or near-complete clinical response was achieved in 37% of patients (18/49), with 5 of these initial responders subsequently developing local recurrence.
- Local failure rates showed no statistically significant difference between long-course chemoradiotherapy and short-course radiotherapy regimens (P=0.51), with distant-only metastasis observed as the primary recurrence pattern.
Read the original sourceJournal of gastrointestinal oncology
